enGene Therapeutics Inc

ENGNNASDAQ · USD
1.89USD0.00 (-21.58%)
529

enGene Therapeutics Inc (ENGN) Covered Calls

Read more

Running ENGN covered calls helps you generate income from enGene Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ENGN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ENGN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ENGN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ENGN covered call is worth writing.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

2026-12-18353.0024.480.050.1564.0026.56276.94-2.07+0.271110.10
2027-03-191263.0024.480.200.3579.0032.7894.96-8.30+0.421110.15
2027-06-172163.0024.480.351.0094.0039.0065.91-14.52+0.5950.65

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank—
  • Market cap (M$)127
  • 52 weeks high-84.57%
  • 52 weeks low35.00%
  • Analyst recommendationBuy
    1.70
  • Target price$4.38
    131.75% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-22
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.08
  • EPS growth next 5 years20.71%

As of Nov 16, 2026